Rottapharm plans debut high yield bond as step towards IPO
Rottapharm Madaus, an Italian-German pharmaceutical company, is looking to raise €400m in its debut bond issue. The planned notes are senior unsecured, have a 2019 maturity and are callable after three years.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts